August 22, 2024 07:14 AM EDTUpdated 11:04 AM
Pharma

Bio­gen, Ei­sai’s Leqem­bi wins UK ap­proval, but not im­me­di­ate NHS cov­er­age

Ayisha Sharma

News Reporter

Bio­gen and Ei­sai’s Leqem­bi has been au­tho­rized by the UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency for Alzheimer’s dis­ease, but a neg­a­tive opin­ion from the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

Charles Riv­er to lay off 3% of staffers as it stream­lines spend­ing

Ful­crum's Phase 3 for old GSK drug fails, stock sinks

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

A service from the Financial Times